HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.

Abstract
The therapy of ITP has recently been revolutionized with the introduction of thrombopoeitin stimulating agents. However, these medications are known to increase the platelet count only while the medication is being administered, with a rapid fall of the platelet count to baseline pre-therapy levels on discontinuation. We report the case of a patient with chronic refractory ITP who has attained a prolonged remission after a short course of eltrombopag, with normalization of the platelet count, which is sustained 8 months after discontinuation of the medication.
AuthorsV Noronha, S D Philip, A Joshi, K Prabhash
JournalInternational journal of hematology (Int J Hematol) Vol. 96 Issue 3 Pg. 380-2 (Sep 2012) ISSN: 1865-3774 [Electronic] Japan
PMID22851056 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Benzoates
  • Hydrazines
  • Pyrazoles
  • eltrombopag
Topics
  • Benzoates (administration & dosage, therapeutic use)
  • Chronic Disease
  • Humans
  • Hydrazines (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic (drug therapy)
  • Pyrazoles (administration & dosage, therapeutic use)
  • Remission Induction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: